Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study

We conducted a phase II trial to investigate the safety and efficacy of alemtuzumab in treating steroid-refractory acute graft-versus-host disease (aGVHD) grade II or higher after stem cell transplantation. Ten adult patients (6 with aGVHD grade III and 4 with aGVHD grade IV) were included in the st...

Descripción completa

Detalles Bibliográficos
Autores: Martinez, Carmen, Solano, Carlos, Ferra, Christelle, Sampol Mayol, Antonia, Valcarcel, David, Perez-Simon, Jose Antonio, Spanish Grp Stem Cell Transplantat
Tipo de recurso: artículo
Fecha de publicación:2009
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/17379
Acceso en línea:https://hdl.handle.net/20.500.13003/17379
Access Level:acceso abierto
Palabra clave:Gastrointestinal Diseases
Steroids
Skin Diseases
Survival Rate
Treatment Outcome
Female
Salvage Therapy
Male
Graft vs Host Disease
Opportunistic Infections
Alemtuzumab
Middle Aged
Antineoplastic Agents
Cause of Death
Aged
Young Adult
Acute Disease
Antibodies, Neoplasm
Hematopoietic Stem Cell Transplantation
Adult
Antibodies, Monoclonal
Humans
Antibodies, Monoclonal, Humanized
Liver Diseases
Enfermedad Aguda
Anticuerpos Monoclonales
Anciano
Masculino
Antineoplásicos
Enfermedades Gastrointestinales
Anticuerpos Monoclonales Humanizados
Trasplante de Células Madre Hematopoyéticas
Humanos
Terapia Recuperativa
Persona de Mediana Edad
Adulto Joven
Causas de Muerte
Hepatopatías
Femenino
Infecciones Oportunistas
Enfermedad Injerto contra Huésped
Tasa de Supervivencia
Esteroides
Resultado del Tratamiento
Anticuerpos Antineoplásicos
Enfermedades de la Piel
Adulto
Acute graft-versus-host disease
Allogeneic stem cell transplantation
id ES_6c4e739b126dbeefc3e13216d474eeb7
oai_identifier_str oai:docusalut.com:20.500.13003/17379
network_acronym_str ES
network_name_str España
repository_id_str
spelling Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II StudyMartinez, CarmenSolano, CarlosFerra, ChristelleSampol Mayol, AntoniaValcarcel, DavidPerez-Simon, Jose AntonioSpanish Grp Stem Cell TransplantatGastrointestinal DiseasesSteroidsSkin DiseasesSurvival RateTreatment OutcomeFemaleSalvage TherapyMaleGraft vs Host DiseaseOpportunistic InfectionsAlemtuzumabMiddle AgedAntineoplastic AgentsCause of DeathAgedYoung AdultAcute DiseaseAntibodies, NeoplasmHematopoietic Stem Cell TransplantationAdultAntibodies, MonoclonalHumansAntibodies, Monoclonal, HumanizedLiver DiseasesEnfermedad AgudaAnticuerpos MonoclonalesAncianoMasculinoAntineoplásicosEnfermedades GastrointestinalesAnticuerpos Monoclonales HumanizadosTrasplante de Células Madre HematopoyéticasHumanosTerapia RecuperativaPersona de Mediana EdadAdulto JovenCausas de MuerteHepatopatíasFemeninoInfecciones OportunistasEnfermedad Injerto contra HuéspedAlemtuzumabTasa de SupervivenciaEsteroidesResultado del TratamientoAnticuerpos AntineoplásicosEnfermedades de la PielAdultoAcute graft-versus-host diseaseAlemtuzumabAllogeneic stem cell transplantationWe conducted a phase II trial to investigate the safety and efficacy of alemtuzumab in treating steroid-refractory acute graft-versus-host disease (aGVHD) grade II or higher after stem cell transplantation. Ten adult patients (6 with aGVHD grade III and 4 with aGVHD grade IV) were included in the study. Nine patients had gastrointestinal tract involvement, 7 had skin involvement, and 5 had liver involvement. Five patients responded to treatment, 2 with complete response and 3 with partial response. Eight infectious events (4 of grade 3-4) and 7 cytomegalovirus (CMV) reactivations were observed. Six patients had grade 3-4 cytopenia. All 10 patients died (7 resulting from aGVHD progression, 2 from severe infection, and I from to leukemia relapse), at a median of 40 days (range, 4 to 88 days) after alemtuzumab treatment. Overall, our findings suggest that steroid-refractory aGVHD may be improved by treatment with alemtuzumab, but that this treatment does not overcome the dismal prognosis of patients with severe aGVHD, demonstrating the need for alternative therapies to treat this complication.Elsevier Science Inc20092009-05-0120092009-05-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/17379reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/173792026-06-22T12:44:07Z
dc.title.none.fl_str_mv Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study
title Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study
spellingShingle Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study
Martinez, Carmen
Gastrointestinal Diseases
Steroids
Skin Diseases
Survival Rate
Treatment Outcome
Female
Salvage Therapy
Male
Graft vs Host Disease
Opportunistic Infections
Alemtuzumab
Middle Aged
Antineoplastic Agents
Cause of Death
Aged
Young Adult
Acute Disease
Antibodies, Neoplasm
Hematopoietic Stem Cell Transplantation
Adult
Antibodies, Monoclonal
Humans
Antibodies, Monoclonal, Humanized
Liver Diseases
Enfermedad Aguda
Anticuerpos Monoclonales
Anciano
Masculino
Antineoplásicos
Enfermedades Gastrointestinales
Anticuerpos Monoclonales Humanizados
Trasplante de Células Madre Hematopoyéticas
Humanos
Terapia Recuperativa
Persona de Mediana Edad
Adulto Joven
Causas de Muerte
Hepatopatías
Femenino
Infecciones Oportunistas
Enfermedad Injerto contra Huésped
Alemtuzumab
Tasa de Supervivencia
Esteroides
Resultado del Tratamiento
Anticuerpos Antineoplásicos
Enfermedades de la Piel
Adulto
Acute graft-versus-host disease
Alemtuzumab
Allogeneic stem cell transplantation
title_short Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study
title_full Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study
title_fullStr Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study
title_full_unstemmed Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study
title_sort Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study
dc.creator.none.fl_str_mv Martinez, Carmen
Solano, Carlos
Ferra, Christelle
Sampol Mayol, Antonia
Valcarcel, David
Perez-Simon, Jose Antonio
Spanish Grp Stem Cell Transplantat
author Martinez, Carmen
author_facet Martinez, Carmen
Solano, Carlos
Ferra, Christelle
Sampol Mayol, Antonia
Valcarcel, David
Perez-Simon, Jose Antonio
Spanish Grp Stem Cell Transplantat
author_role author
author2 Solano, Carlos
Ferra, Christelle
Sampol Mayol, Antonia
Valcarcel, David
Perez-Simon, Jose Antonio
Spanish Grp Stem Cell Transplantat
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Gastrointestinal Diseases
Steroids
Skin Diseases
Survival Rate
Treatment Outcome
Female
Salvage Therapy
Male
Graft vs Host Disease
Opportunistic Infections
Alemtuzumab
Middle Aged
Antineoplastic Agents
Cause of Death
Aged
Young Adult
Acute Disease
Antibodies, Neoplasm
Hematopoietic Stem Cell Transplantation
Adult
Antibodies, Monoclonal
Humans
Antibodies, Monoclonal, Humanized
Liver Diseases
Enfermedad Aguda
Anticuerpos Monoclonales
Anciano
Masculino
Antineoplásicos
Enfermedades Gastrointestinales
Anticuerpos Monoclonales Humanizados
Trasplante de Células Madre Hematopoyéticas
Humanos
Terapia Recuperativa
Persona de Mediana Edad
Adulto Joven
Causas de Muerte
Hepatopatías
Femenino
Infecciones Oportunistas
Enfermedad Injerto contra Huésped
Alemtuzumab
Tasa de Supervivencia
Esteroides
Resultado del Tratamiento
Anticuerpos Antineoplásicos
Enfermedades de la Piel
Adulto
Acute graft-versus-host disease
Alemtuzumab
Allogeneic stem cell transplantation
topic Gastrointestinal Diseases
Steroids
Skin Diseases
Survival Rate
Treatment Outcome
Female
Salvage Therapy
Male
Graft vs Host Disease
Opportunistic Infections
Alemtuzumab
Middle Aged
Antineoplastic Agents
Cause of Death
Aged
Young Adult
Acute Disease
Antibodies, Neoplasm
Hematopoietic Stem Cell Transplantation
Adult
Antibodies, Monoclonal
Humans
Antibodies, Monoclonal, Humanized
Liver Diseases
Enfermedad Aguda
Anticuerpos Monoclonales
Anciano
Masculino
Antineoplásicos
Enfermedades Gastrointestinales
Anticuerpos Monoclonales Humanizados
Trasplante de Células Madre Hematopoyéticas
Humanos
Terapia Recuperativa
Persona de Mediana Edad
Adulto Joven
Causas de Muerte
Hepatopatías
Femenino
Infecciones Oportunistas
Enfermedad Injerto contra Huésped
Alemtuzumab
Tasa de Supervivencia
Esteroides
Resultado del Tratamiento
Anticuerpos Antineoplásicos
Enfermedades de la Piel
Adulto
Acute graft-versus-host disease
Alemtuzumab
Allogeneic stem cell transplantation
description We conducted a phase II trial to investigate the safety and efficacy of alemtuzumab in treating steroid-refractory acute graft-versus-host disease (aGVHD) grade II or higher after stem cell transplantation. Ten adult patients (6 with aGVHD grade III and 4 with aGVHD grade IV) were included in the study. Nine patients had gastrointestinal tract involvement, 7 had skin involvement, and 5 had liver involvement. Five patients responded to treatment, 2 with complete response and 3 with partial response. Eight infectious events (4 of grade 3-4) and 7 cytomegalovirus (CMV) reactivations were observed. Six patients had grade 3-4 cytopenia. All 10 patients died (7 resulting from aGVHD progression, 2 from severe infection, and I from to leukemia relapse), at a median of 40 days (range, 4 to 88 days) after alemtuzumab treatment. Overall, our findings suggest that steroid-refractory aGVHD may be improved by treatment with alemtuzumab, but that this treatment does not overcome the dismal prognosis of patients with severe aGVHD, demonstrating the need for alternative therapies to treat this complication.
publishDate 2009
dc.date.none.fl_str_mv 2009
2009-05-01
2009
2009-05-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.13003/17379
url https://hdl.handle.net/20.500.13003/17379
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier Science Inc
publisher.none.fl_str_mv Elsevier Science Inc
dc.source.none.fl_str_mv reponame:Docusalut
instname:Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
reponame_str Docusalut
collection Docusalut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410258500190208
score 15,81155

Similares en LA Referencia